Abstract
Type 2 diabetes mellitus (T2DM) is a serious health problem with epidemic proportions and associated with high cardiovascular morbidity and mortality. Thus, the prevention or at least delaying the onset of T2DM is imperative. Subjects with impaired glucose metabolism (prediabetes) are highly likely to develop overt T2DM. Treatment of accompanied cardiovascular risk factors, such as hypertension and dyslipidemia, in these patients is frequently complicated as it can impair the already altered glucose homeostasis. This review discusses the pathophysiology of lipid disorders and hypertension in prediabetes along with the effects of lipid modifying and antihypertensive drugs in glucose/insulin metabolism. A critical overview and suggestions of different treatment options for prediabetic patients with dyslipidemia and/or hypertension are also presented.
Keywords: Aldosterone, angiotensin, dyslipidemia, fibrates, hypertension, new-onset diabetes, prediabetes, statins.
Current Pharmaceutical Design
Title:How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Volume: 19 Issue: 21
Author(s): Vasilios Tsimihodimos, Matilda Florentin and Moses S. Elisaf
Affiliation:
Keywords: Aldosterone, angiotensin, dyslipidemia, fibrates, hypertension, new-onset diabetes, prediabetes, statins.
Abstract: Type 2 diabetes mellitus (T2DM) is a serious health problem with epidemic proportions and associated with high cardiovascular morbidity and mortality. Thus, the prevention or at least delaying the onset of T2DM is imperative. Subjects with impaired glucose metabolism (prediabetes) are highly likely to develop overt T2DM. Treatment of accompanied cardiovascular risk factors, such as hypertension and dyslipidemia, in these patients is frequently complicated as it can impair the already altered glucose homeostasis. This review discusses the pathophysiology of lipid disorders and hypertension in prediabetes along with the effects of lipid modifying and antihypertensive drugs in glucose/insulin metabolism. A critical overview and suggestions of different treatment options for prediabetic patients with dyslipidemia and/or hypertension are also presented.
Export Options
About this article
Cite this article as:
Tsimihodimos Vasilios, Florentin Matilda and S. Elisaf Moses, How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?, Current Pharmaceutical Design 2013; 19 (21) . https://dx.doi.org/ 10.2174/13816128113199990304
DOI https://dx.doi.org/ 10.2174/13816128113199990304 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer?s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Specific and Sensitive RP-HPLC Method Development and Validation for the Determination of Aripiprazole: Application in Preformulation Screening of Nanoemulsion
Current Nanomedicine Liver Disease in Diabetes Mellitus: Potential Therapeutic Value of Vitamin E-Silybin Phytosomal Complex
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Therapeutic Paradigms in Glioblastoma
Reviews on Recent Clinical Trials Racial Differences in Gray Matter Integrity by Diffusion Tensor in Black and White Octogenarians
Current Alzheimer Research The Optimal Treatment of Severe Hypertension in Pregnancy: Update of the Role of Nicardipine
Current Pharmaceutical Biotechnology Does Oral Metoprolol have Any Effect on the Functional Parameters and Perfusion Defects of the Left Ventricle?
Current Medical Imaging Membrane Bound Members of the M1 Family: More Than Aminopeptidases
Protein & Peptide Letters Progress Towards Clinically Useful Aldosterone Synthase Inhibitors
Current Topics in Medicinal Chemistry Is Beta-Blocker Treatment Associated with a Decrease in the Risk of Cancer
Letters in Drug Design & Discovery Interactions Between Hypertension and Hypercholesterolemia: From Epidemiology to Therapeutic Implications
Current Hypertension Reviews Mitochondria-Targeted Drugs
Current Molecular Pharmacology Risk and Benefit of Statins in Stroke Secondary Prevention
Current Vascular Pharmacology Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders
Current Pharmaceutical Design Pure Polyphenols Applications for Cardiac Health and Disease
Current Pharmaceutical Design Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Molecular and Biotechnological Advances in Milk Proteins in Relation to Human Health
Current Protein & Peptide Science Cardiovascular effect of Nigella sativa L. Aqueous Extract in Normal Rats
Cardiovascular & Hematological Disorders-Drug Targets PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Physical Function and Exercise in Older Patients with Cardiovascular and Respiratory Conditions
Current Pharmaceutical Design